pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,630 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1837Endpoints1422Fierce Biotech743BioSpace733BioPharma Dive541raps242onclive165fda recalls
therapy area
allOncology12684Rare Disease3289Immunology2967Cardiology2833Hematology2240Pulmonology2219Vaccines
  • Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at risk
    Ionis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
    BioSpace · 3d agoEarningsNegative↗ source
  • HHS commits up to $25M for ibogaine and other psychotropic drugs on Veteran's Day
    HHS announced an investment of up to $25 million for ibogaine and other rapid acting psychotropic medicines aimed at serious mental illnesses such as PTSD, unveiled on Veteran's Day. Up to $4.9 mi…
    BioSpace · 3d agoDealPositive↗ source
← prev
page 3 of 146
next →
116
fda medwatch112
globenewswire health73
fda press59
1822
Psychiatry & CNS1225
Ophthalmology1121
Endocrinology & Metabolism794
Pain784
Nephrology767
  • HHS to allocate up to $4.9 million for ibogaine research targeting PTSD
    The U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…
    STAT · 3d agoRegulatoryNeutral↗ source
  • Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trial
    Regeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…
    BioSpace · 3d agoPositive readoutPositive↗ source
  • Setbacks in two heart disease trials raise questions about future cardiovascular drug research
    A recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…
    STAT · 3d agoNegative readoutNegative↗ source
  • Oura to acquire telehealth firm Counsel Health, raising conflict-of-interest concerns for Eli Lilly
    Oura, known for its smart rings, announced it will purchase Counsel Health, a telehealth startup that connects patients with clinicians for GLP-1 prescriptions. The acquisition will give Counsel c…
    STAT · 3d agoDealNeutral↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…
    raps · 3d agoRegulatoryNegative↗ source
  • Medicaid work requirement enforcement delayed six months to July 2027
    The Trump administration announced that states will now have an additional six months before they must begin enforcing the new Medicaid work requirements, pushing the start date to July 1, 2027. T…
    STAT · 2d agoRegulatoryNeutral↗ source
  • Doctors question Boston Scientific's Watchman marketing after FDA approval
    Boston Scientific's Watchman cardiac implant has been placed in more than 800,000 patients worldwide. The device eventually secured FDA approval after a protracted review, but the clearance was li…
    STAT · 3d agoRegulatoryNegative↗ source
  • Windward Bio raises $175M in IPO, boosting 2026 biotech debut count to 35
    Windward Bio completed an initial public offering that raised about $175 million, selling roughly 10.3 million shares at $17 each on the Nasdaq. The proceeds are earmarked to advance its lead antib…
    BioSpace · 3d agoDealPositive↗ source
  • Senators propose bill to limit conflicts of interest on preventive services task force
    Two senators, Angus King of Maine and Elizabeth Warren of Massachusetts, announced legislation aimed at tightening conflict‑of‑interest rules for the U.S. Preventive Services Task Force, the panel…
    STAT · 3d agoRegulatoryNeutral↗ source
  • ObesityWeek 2026 to showcase amylin pathway and emerging weight-loss mechanisms
    ObesityWeek 2026 starts Saturday in Washington, DC, gathering weight-loss experts and biopharma companies with metabolic assets. The meeting will highlight the amylin pathway and other emerging me…
    BioSpace · 3d agoNeutral↗ source
  • Democrats rally behind 'Medicare for More' and 'Medikids' health coverage proposals
    Democrats are aligning around two health-care proposals aimed at expanding coverage. The "Medicare for More" plan seeks to extend Medicare to a larger share of the population, potentially all Amer…
    STAT · 2d agoNeutral↗ source
  • Synchron pauses second-generation brain-computer interface trial, says pause not safety related
    Synchron, a brain-implant startup, announced it is pausing enrollment in its second-generation brain-computer interface trial. Company officials emphasized the decision is operational and not driv…
    STAT · 3d agoNeutral↗ source
  • Investigation reveals U.S. fertility clinics offering unproven three-parent IVF to older women despite safety concerns
    The probe began after a British couple reported that they had paid a U.S.-based firm, International Fertility Group, large sums to travel abroad for an experimental fertility method that is not per…
    STAT · 3d agoNegative↗ source
  • Addiction Society Issues First Guidance on Managing Medetomidine Withdrawal
    The American Society of Addiction Medicine (ASAM) has published its first national guidance for clinicians on how to identify and treat patients experiencing withdrawal from medetomidine, a sedativ…
    STAT · 3d agoNegative↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The FDA sent warning letters to three active pharmaceutical ingredient manufacturers based in China. Two firms were cited for refusing the agency's requests for records, while the third was found…
    raps · 3d agoRegulatoryNeutral↗ source
  • New organ donation rules criticized for pressuring grieving families
    A neurologist at Oregon Health & Science University recounts the case of a 22-year-old woman who was declared brain dead after a traffic accident and became a donor. He describes the intensive moni…
    STAT · 3d agoRegulatoryNegative↗ source
  • Senator-elect Abdul El-Sayed vows to rebuild trust in science amid rising measles and other health threats
    Senator-elect Abdul El‑Sayed is set to become the first epidemiologist to serve in the U.S. Senate, a timing that coincides with a series of public‑health challenges across the country. More than…
    STAT · 3d agoNeutral↗ source
  • Cerevance appoints Karl Kieburtz as new chief medical officer
    STAT+ runs a regular column that tracks personnel moves in the pharmaceutical sector. The piece highlights recent hires, promotions and transfers across companies. Cerevance announced that Karl Ki…
    STAT · 3d agoNeutral↗ source
  • New Alzheimer’s biomarker tests raise existential concerns for people without symptoms
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, reflects on the personal impact of learning one may develop Alzheimer’s before any symptoms appear. He fram…
    STAT · 3d agoNeutral↗ source
  • Local schools launch experiments to curb teen phone addiction
    A teacher in Milwaukee asked her digital journalism class to write about their relationship with devices, uncovering disturbing accounts of constant phone use and online abuse. The students descri…
    STAT · 3d agoNegative↗ source
  • Cellectis could cut 70% of workforce in shift to in vivo therapies
    Cellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.
    BioSpace · 3d ago↗ source
  • Eli Lilly’s Mounjaro and Merck’s oral PCSK9 inhibitor win FDA nod amid string of cardiovascular trial setbacks
    The cardiovascular drug development landscape entered the American Heart Association’s Scientific Sessions with a mix of optimism and disappointment. Recent months have seen several late‑stage tria…
    BioSpace · 4d agoRegulatoryNeutral↗ source
  • Neurosterix raises $105M Series B to advance oral M4 schizophrenia drug and adds former Karuna leaders
    Neurosterix, a spinout from Addex Therapeutics, announced a $105 million Series B financing. The round was led by RTW Investments with participation from GV, Janus Henderson Investors and others. A…
    BioSpace · 4d agoDealPositive↗ source